MEI Pharma, Inc. (MEIP)

[bladerunner1717]

Rivervalley,

BLUE took the whole biotech sector down with it. CAR-T is not going to be the imminent treatment/cure many people were expecting/hoping for. JUNO, KITE and BLUE all have/had multi-billion dollar valuations with nothing close to commercialization. The technology may be a decade out, before all the kinks are worked out.

All in all, ASH was rather a disappointment. Adam Feuerstein remarked that no one could have predicted that if you shorted all the companies presenting at ASH, you would have made a tidy sum.

Having the broad market down in triple digits didn't help, either.

But, at least, we FINALLY got the Phase III announcement that we were hoping for. Now Gold needs to find a partner for the Phase III. Micro-cap biotechs don't have a good record of trying to bring an oncology drug through Phase III's on their own.


Bladerunner